TY - JOUR
T1 - Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog
AU - Lashkari, Harsha Prasada
AU - Nash, Ruth
AU - Albanese, Assunta
AU - Okoye, Bruce
AU - Millar, Robert
AU - Pritchard-Jones, Kathy
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.
AB - Sertoli-Leydig cell tumors are rare ovarian neoplasms. We report two unusual cases with bilateral SLCTs suggesting evidence of genetic predisposition and at high risk of recurrence. To reduce this risk, we exploited the use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors. We used it as maintenance antitumor therapy for 2 years after completion of chemotherapy, to cover the period of risk for recurrence. Both patients remain in complete remission at >2 years after completing leuprorelin therapy. Of note, both patients carry DICER1 mutations, frequently found in pleuropulmonary blastoma syndrome.
UR - http://www.scopus.com/inward/record.url?scp=84876437926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876437926&partnerID=8YFLogxK
U2 - 10.1002/pbc.24382
DO - 10.1002/pbc.24382
M3 - Article
C2 - 23193086
AN - SCOPUS:84876437926
SN - 1545-5009
VL - 60
SP - E16-E18
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 6
ER -